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INTRODUCTION
The excellent review article published in
Frontiers in Pharmacology by Antor et al.
(9 April 2014), concludes: “Clinical tri-
als with transdermal scopolamine have
consistently demonstrated its safety and
efficacy in postoperative nausea and vom-
iting (PONV). Thus, scopolamine is a
promising candidate for the management
of PONV in adults as a first line monother-
apy or in combination with other drugs. In
addition, transdermal scopolamine might
be helpful in preventing postoperative dis-
charge nausea and vomiting owing to its
long-lasting clinical effects.”
We believe a cautionary note is required
before granting unrestricted endorsement
to this treatment. In our experience, the
use of scopolamine in the elderly may
trigger episodes of amnestic delirium.
The following case exemplifies the effect
of transdermal scopolamine for preven-
tion of motion sickness during a vacation
ship cruise by a previously normal elderly
woman.
CASE REPORT
A healthy, young-looking, intelligent and
cheerful 80-year-old woman was evalu-
ated at the Houston Methodist Hospital
Memory Clinic because of an episode of
“scopolamine intoxication” that occurred
on November 12, 2010. She flew from
Texas to Hawaii and prior to boarding
a cruise ship applied a post-auricular
transdermal scopolamine patch to prevent
seasickness. Her last memories of the
vacation include arriving to Hawaii and
boarding the cruise ship. She has no recol-
lection after becoming confused, delirious,
agitated, and experiencing visual halluci-
nations. Because of her markedly altered
mental status she was disembarked, admit-
ted to a local hospital in Hawaii and even-
tually flown back to Texas 5 days later.
On November 30, 2010 her neurolog-
ical and neuropsychological evaluation
was consistent with Mild Cognitive
Impairment - Amnestic type. A 2-deoxy-
2-(18F)fluoro-D-glucose (FDG) positron
emission tomography (PET) brain scan
showed markedly increased tracer uptake
in the basal ganglia bilaterally (Figure 1,
top). The standardized uptake value
(SUV) in basal ganglia was 20, with a basal
ganglia to parietal cortex ratio of 2.1. Since
her clinical course was so acute with rapid
resolution over a 6- to 8-week period it
was felt that she did not have demen-
tia. She completely recovered from this
episode and a PET scan was repeated on
October 25, 2011 showing a near-normal
tracer distribution in the basal ganglia and
cortex. The SUV of the basal ganglia was
now 12, which is normal, and the basal
ganglia to cortex ratio was now 1.5, also
normal (Figure 1, bottom).
DISCUSSION
In our experience, scopolamine-induced
amnestic delirium in the elderly is not
exceptional. Seo et al. (2009) reported 7
women with similar presentations seen
at their Memory Clinic in a period of
6 years with a mean age of 72.4 years
(range, 65–82 years). These authors found
seven additional cases reported in the lit-
erature ranging in age from 60 to 84
years. We believe these untoward scopo-
lamine effects are not to be found in
the young-age patients in surgical series
of elective cesarean sections, or in out-
patient laparoscopic, plastic surgery, or
breast augmentation surgery compiled by
Antor et al. (2014). This may be due to
the aging brain’s particular susceptibility
to central nervous system (CNS) drugs.
While anticholinergic drug use in older
adults has been cautioned for many years,
scopolamine specifically only made it to
the Beers Criteria in 2012 (The American
Geriatrics Society, 2012).
The transdermal scopolamine patch
applied to the post-auricular area contains
1.5mg of scopolamine; the system releases
in-vivo approximately 1.0mg of scopo-
lamine over a 72-h period with an aver-
age plasma concentration of 87 pg/mL
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FIGURE 1 | Top:Axial brain slices of a 2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography
(FDG-PET) scan dated 11/30/10: left slice= level of temporal lobes, middle= basal ganglia, right=
frontal and parietal cortex. Scan shows markedly increased tracer uptake in the basal ganglia (arrow
indicates left striatum), which appears striking against the normal uptake diffusely in the cortex. Basal
ganglia to cortex ratio= 2.1. This finding has not been described consistently for any neurological
disorder and is presumably secondary to scopolamine. Color bar indicates standardized uptake value
(SUV) and runs from 0 (black) to 14 (white). On this display scale, the basal ganglia are actually “burned
out” bright, with an SUV of 20. Bottom: FDG-PET performed on 10/25/11 demonstrating essentially
normal tracer uptake in the basal ganglia (arrow) and cortex. The basal ganglia to cortex ratio= 1.5. This
represents a dramatic improvement from the previous scan. The striking interval improvement in the
scan supports the hypothesis that the original PET abnormality was a medication effect. Color bar
indicates SUV and runs from 0 (black) to 14 (white).
of free scopolamine; detectable lev-
els are found within 4 h with a peak
level at 24 h (reviewed by Antor et al.,
2014). Scopolamine is a high-affinity
selective competitive antagonist of G
protein-coupled muscarinic receptor for
acetylcholine. Scopolamine penetrates
the blood-brain barrier, readily block-
ing cholinergic transmission in the CNS.
It not only affects the vestibular nuclei and
the vomiting center, but also the extensive
cholinergic network that originates in the
Nucleus Basalis of Meynert.
We hypothesize that the CNS choliner-
gic blocking effect of scopolamine induces
a “cholinergic stress test” resulting in
amnestic delirium in elderly patients who
have low central cholinergic reserves as
a result of age, subclinical Alzheimer’s
disease, or vascular lesions affecting the
cholinergic pathways in the periventricu-
lar white matter. It is well demonstrated
that the elderly are more sensitive to
the cognitive effects of scopolamine than
young individuals, probably due to cen-
tral cholinergic system deficits associated
with aging (Flicker et al., 1992; Naranjo
et al., 2000). Age is also relevant in the
reversible reduction of cerebral blood flow
and glucose consumption produced by
cholinergic blockage induced by scopo-
lamine (Blin et al., 1997).
The effects of acute muscarinic block-
ade on brain glucose metabolism have
not been well studied, but we found a
striking and reversible hypermetabolism
of the basal ganglia, a very unusual
finding on PET imaging. The mecha-
nism of the effect is far from under-
stood, but muscarinic cholinergic synapses
exert powerful and complex effects on
neurotransmission in the basal ganglia,
with muscarinic receptors mediating a
wide variety of excitatory and inhibitory
effects in both the direct and indi-
rect pathways (reviewed by Benarroch,
2012). Muscarinic synapses are also widely
present in the cortex and likely con-
tribute importantly to the scopolamine
clinical effect we observed, but this neu-
rochemical change did not produce a
detectable effect on glucose metabolism in
the cortex.
In summary, we believe that the trans-
dermal scopolamine patch for prevention
of PONV or motion sickness should be
used with caution in most elderly patients.
This group includes those with a his-
tory of glaucoma or urinary problems.
Scopolamine should be avoided com-
pletely in subjects with a diagnosis of
Mild Cognitive Impairment or when the
patient’s relatives acknowledge the occur-
rence of age-related memory loss.
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